JPH0158163B2 - - Google Patents
Info
- Publication number
- JPH0158163B2 JPH0158163B2 JP10317382A JP10317382A JPH0158163B2 JP H0158163 B2 JPH0158163 B2 JP H0158163B2 JP 10317382 A JP10317382 A JP 10317382A JP 10317382 A JP10317382 A JP 10317382A JP H0158163 B2 JPH0158163 B2 JP H0158163B2
- Authority
- JP
- Japan
- Prior art keywords
- hepatocytes
- compound
- liver
- test
- dme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 claims description 7
- 208000019423 liver disease Diseases 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 150000004662 dithiols Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 22
- 210000003494 hepatocyte Anatomy 0.000 description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000001243 protein synthesis Methods 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000030090 Acute Disease Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001278 effect on cholesterol Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10317382A JPS58222019A (ja) | 1982-06-16 | 1982-06-16 | 肝疾患治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10317382A JPS58222019A (ja) | 1982-06-16 | 1982-06-16 | 肝疾患治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58222019A JPS58222019A (ja) | 1983-12-23 |
| JPH0158163B2 true JPH0158163B2 (es) | 1989-12-11 |
Family
ID=14347110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10317382A Granted JPS58222019A (ja) | 1982-06-16 | 1982-06-16 | 肝疾患治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58222019A (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992010176A1 (en) * | 1990-12-07 | 1992-06-25 | Taisho Pharmaceutical Co., Ltd. | Therapeutic agent for hepatic disease |
-
1982
- 1982-06-16 JP JP10317382A patent/JPS58222019A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992010176A1 (en) * | 1990-12-07 | 1992-06-25 | Taisho Pharmaceutical Co., Ltd. | Therapeutic agent for hepatic disease |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58222019A (ja) | 1983-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0276317B1 (en) | Gamma-l-glutamyl-l-cysteine ethyl ester and drug containing it as effective ingredient | |
| EP3103459B1 (en) | Sulphated hyaluronic acids as antiviral agents | |
| US6165515A (en) | Method for treatment of osteoporosis | |
| US20210069192A1 (en) | Use of neutrophil elastase inhibitors in liver disease | |
| WO2005058331A1 (en) | Use of gallium to treat inflammatory arthritis | |
| CN111635309B (zh) | 一种新型解热镇痛药物及其制备方法和用途 | |
| KR20170125991A (ko) | 실리빈 및 ve 함유 약학 조성물 | |
| JP2001520994A (ja) | 消化管疾患を治療するためにクマリン誘導体を用いる用途 | |
| CA1106285A (en) | Process for obtaining a natural polar fraction having anti-psoriatic activity | |
| Wang et al. | Puerarin Ameliorates 5-Fluorouracil–Induced Intestinal Mucositis in Mice by Inhibiting JAKs | |
| WO1988000048A1 (en) | Drug for prophylaxis and treatment of hepatopathy | |
| TW201313229A (zh) | 改善自體免疫病如慢性風濕之治療方法 | |
| JP3102945B2 (ja) | 肝炎治療剤 | |
| JPH0158163B2 (es) | ||
| CN102552280A (zh) | 甘草酸或盐及其衍生物的制药用途 | |
| JP3130368B2 (ja) | 肝機能改善薬 | |
| JP3969831B2 (ja) | ハイドロキシプロリン誘導体 | |
| US4080442A (en) | Disaccharide derivatives used in the treatment of hepatic diseases | |
| WO1999047546A1 (fr) | Derives d'hydroxyproline | |
| JPH11505503A (ja) | 有機塩基カチオンとの２−〔（２，６−ジクロロフェニル）アミン〕フェニルアセトキシ酢酸の新規の塩類 | |
| JPH11209282A (ja) | ベルゲニン及びその誘導体を有効成分とする肝機能改善剤 | |
| JPH1179992A (ja) | アポトーシス抑制剤 | |
| EP0301466B1 (en) | Uricosuric composition | |
| JP2001335503A (ja) | ラジカル消去用医薬品 | |
| JPH03232870A (ja) | チオアミド化合物 |